Rare Hereditary Cardiac Amyloidosis Treated With SGLT2 Inhibitor

Jakob Christoph Voran, Željka Radić, Lucia Sophie Kilian, Felix Braun, Christoph Röcken, Derk Frank, Hatim Seoudy · 2026

Read Rare Hereditary Cardiac Amyloidosis Treated With SGLT2 Inhibitor by Jakob Christoph Voran, Željka Radić, Lucia Sophie Kilian, Felix Braun, Christoph Röcken, Derk Frank, Hatim Seoudy (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13616553.txt.

Description

Jakob Christoph Voran and co-authors published this case report in 2026. A sixty-one-year-old man arrived with worsening heart failure. His history included carpal tunnel syndrome in wrists, kidney disease, and a family shadow: his brother had amyloidosis, and their mother likely died of it. Heart imaging showed the thickened, stiff walls typical of cardiac amyloidosis, a disease where misfolded protein clogs the heart. The usual causes were tested and excluded.

Genetic testing found the culprit: a mutation in apolipoprotein A-I, a hereditary form of the disease. A stomach biopsy confirmed that protein in his tissue. He was treated with dapagliflozin, a drug from the SGLT2 inhibitor family first developed for diabetes. His condition improved. The authors stress hereditary types belong on the checklist when amyloidosis has no cause. They advise screening relatives, and they float this drug class as a treatment option.

Catalog record

CREATORJakob Christoph Voran, Željka Radić, Lucia Sophie Kilian, Felix Braun, Christoph Röcken, Derk Frank, Hatim Seoudy
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE13 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13616553

Browse the full library · About the Tower of Babel